Skip to main content
Psych Congress  

Twice Weekly dTMS Monotherapy Was Effective in Maintaining Acute-Phase Responders and Increasing the Response Rate in the Brainsway Multicenter Depression Trial

Authors  
Aron Tendler, MD
Abraham Zangen, PhD
Mark George, MD
Yiftach Roth
Sponsor  
Brainsway Ltd.

This poster was presented at the 29th Annual U.S. Psychiatric & Mental Health Congress, held October 21-24, 2016, in San Antonio, Texas.

Introduction: Deep transcranial magnetic stimulation (dTMS) has been shown to be safe and effective for treatment resistant depression. Our goal was to analyze the efficacy of continuation dTMS monotherapy at twice a week for twelve weeks following the acute phase of four weeks of five times a week treatment in the active arm of the Brainsway multicenter double-blinded depression study. We assessed the probability of response in active dTMS recipients over 16 weeks, and the durability of clinical response among responders at the end of the 4-weeks acute phase, for whom the 12-week continuation phase is a maintenance phase.

Analysis: Kaplan-Meier survival curve (time to event [response]) was used to characterize outcomes during weeks 1 to 16 in the whole sample (n=89) of active dTMS recipients. % of time in response (≥50% decrease in HDRS-21) and in remission (HDRS-21<10) for each patient, and % of patients in response/remission at each time point, were calculated for 4-week responders (n=30) during the continuation phase.

Results: 59/89(66.3%) achieved responder status at any time point. Among the responders at the end of week 4 (n=30), the vast majority of patients showed sustained durability throughout the continuation phase (their maintenance phase). 73.9% ±7.7% of patients were in responder status, and 59.8% ±8.4% of patients were in remission at each time point (weeks 5 to 16). 19/30 (63.3%) patients who responded at the end of week 4 completed the entire 16 weeks. Mean ± SEM of % of time in response out of their total time in the twice weekly phase were 74.7% ±5.4 24/30 patients (80%) were 60% or more of their time in response, and 18/30 patients (60%) were 60% or more of their time in remission.

Conclusions: The vast majority of patients who continued twice weekly dTMS treatments reached response. The odds for a patient to reach response increased with the number of dTMS sessions, even for patients who did not respond for several weeks. Twice weekly dTMS maintenance monotherapy was efficacious for acute phase responders.

Back to Top